

Notice of extraordinary general meeting in LIDDS AB (publ)

The shareholders of LIDDS AB (publ), reg. no. 556580-2856, (the “Company” or “Lidds”), are hereby invited to an extraordinary general meeting on Thursday, 18 December 2025 at 10:00 CET at Excore's premises at Kungsportsavenyen 22, 411 36 Gothenburg.

Right to participate and notice to attend the meeting

Shareholders who are recorded in the share register kept by Euroclear Sweden AB (The Swedish Central Securities Depository Euroclear Sweden AB) as of 10 December 2025 and who have notified the Company of their intention to attend so that the notification is received by the Company no later than 12 December 2025 are entitled to participate in the meeting. The notification shall be sent to LIDDS AB (publ), Kungsportsavenyen 22, 411 36 Gothenburg. The notification may also be submitted electronically and shall then be sent to: info@liddspharma.com.

The notification shall state the full name, personal identification number or company registration number, shareholding, address, telephone number (daytime) and, where applicable, the number of assistants (maximum two). The notification should, where applicable, be accompanied by a power of attorney, certificate of registration, and other authorisation documents.

Nominee-registered shares

To be entitled to participate in the extraordinary general meeting, shareholders who have had their shares registered with a nominee must temporarily re-register the shares in their own name. Shareholders who wish to re-register their voting rights must notify its trustee well in advance before 12 December 2025. The re-registration must be effected with Euroclear Sweden AB on 12 December 2025.

Proxy etc.

If shareholders are to be represented by a proxy, the proxy must bring a written and dated power of attorney signed by the shareholder to the meeting. The power of attorney must not be older than one year, unless a longer validity period (but no more than five years) is specified in the power of attorney. If the power of attorney is issued by a legal entity, the proxy must also bring a current registration certificate or equivalent authorisation document for the legal entity. To facilitate entry at the meeting, a copy of the power of attorney and other authorisation documents should be attached to the notification of attendance at the general meeting. Power of attorney forms are available on the Company's website www.liddspharma.com and will be sent by post to shareholders who contact the Company and state their address.

About the meeting

The Board has appointed Daniel Lifveredson to open the meeting.

Proposed agenda

1. Opening of the meeting.
2. Election of chairman at the meeting.
3. Preparation and approval of the voting list.
4. Approval of the agenda.
5. Election of one or two persons to verify the minutes.
6. Examination of whether the meeting has been duly convened.
7. Resolution on amendment of the articles of association.
8. Resolution to reduce the share capital.
9. Closing of the meeting.

Proposed resolutions

Item 2: The Board of Directors proposes to elect Daniel Lifveredson as chairman of the meeting.

Item 7: The Board of Directors proposes that the general meeting resolve to adopt an updated version of the articles of association, whereby the limits for the Company's share capital are reduced. The reason for the Board's proposal is to enable the reduction in share capital proposed under item 8 on the agenda for the meeting.

The proposed amendment means that the Company's share capital shall amount to a minimum of SEK 500,000 and a maximum of SEK 2,000,000. After the amendment, the articles of association will have the wording set out in **appendix 7**.

The resolution in accordance with this proposal is conditional upon the meeting resolving to reduce the share capital in accordance with item 8 on the agenda.

The Board further proposes that the Board, or the person appointed by the Board, be authorised to make the minor formal adjustments to the articles of association that may prove necessary in connection with registration with the Swedish Companies Registration Office.

Item 8: The Board of Directors proposes that the general meeting resolve to reduce the Company's share capital to cover losses as follows:

- The share capital shall be reduced to cover the accumulated loss.
- The share capital shall be reduced by SEK 6,732,556.278. After the reduction, the share capital shall amount to SEK 500,000.
- The reduction of the share capital shall be carried out without the retirement of shares, which means that the quota value of the shares will be reduced.
- The resolution in accordance with this proposal is conditional upon the general meeting resolving to amend the articles of association in accordance with item 7 on the agenda.

The Board further proposes that the Board, or the person appointed by the Board, be authorised to make any minor formal adjustments to the resolution that may be necessary in connection with registration with the Swedish Companies Registration Office.

Other information

Number of shares and votes

At the time of issuing this notice, the total number of shares in the Company amounts to 136,463,326. The Company does not hold any of its own shares, which means that all shares carry voting rights.

Majority requirements

A valid resolution under item 7 and 8 requires that the proposals are supported by shareholders with at least two thirds of both the votes cast and the shares represented at the general meeting.

Meeting documents

The Board of Directors' complete proposals, together with related documents, will be available on the Company's website, www.liddspharma.com, no later than two weeks before the meeting.

All of the documents above will be sent free of charge to the shareholders who request them from the Company and state their address and will be available on the website.

Right of question

Shareholders are informed of their right pursuant to Chapter 7, Section 32 of the Swedish Companies Act (2005: 551) to request information from the Board of Directors and the CEO at the general meeting regarding circumstances that may affect the assessment of an item on the agenda and circumstances that may affect the Company's and the group's financial situation.

Processing of personal data

For information on how your personal data is processed, please see: <https://www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf>.

Gothenburg in November 2025

The Board of Directors of LIDDS AB (publ)

For additional information, please contact

Mats Wiking, CEO and CFO
Phone: +46 (0)70 620 04 00
E-mail: mats.wiking@liddspharma.com

Daniel Lifveredson, Chairman of the Board
Telefon: +46 (0) 70-916 21 01
Email: d.li@excore.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish pharmaceutical company focused on the development of oncology drugs. LIDDS has a proprietary drug delivery technology, NanoZolid®, on which several projects are based. With NanoZolid, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release and with minimal negative side-effects. In addition to these projects, LIDDS develops proprietary drug candidate NOV202 that have shown very good results in pre-clinical studies. The company is listed on Nasdaq First North Growth market.

Attachments

Notice of extraordinary general meeting in LIDDS AB (publ)
Notification Form To EGM
PoA Form To EGM
Articles Of Association LIDDS AB
The Board's Proposals For Resolutions For EGM